Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb to present new lung cancer data at WCLC 2017

Bristol-Myers Squibb to present new lung cancer data at WCLC 2017

4th October 2017

Bristol-Myers Squibb has announced that it will be sharing new clinical data on Opdivo and other therapies at the 2017 World Conference on Lung Cancer (WCLC).

Organised by the International Association for the Study of Lung Cancer, the conference will take place in Yokohama, Japan from October 15th to 18th, and will see Bristol-Myers Squibb present a total of 28 Opdivo-focused abstracts.

Insights from company-sponsored studies, clinical collaborations and investigator-sponsored research will be shared, including late-breaking data in malignant pleural mesothelioma, and clinical and real-world data showing the benefits of Opdivo in previously-treated advanced non-small cell lung cancer (NSCLC).

Research on Opdivo-based combinations in advanced NSCLC and patient-reported outcomes in advanced small cell lung cancer will also be shared.

Dr Nick Botwood, development lead for thoracic cancers at Bristol-Myers Squibb, said: "Bristol-Myers Squibb is dedicated to driving scientific innovation and investigating potential treatment options for patients with difficult-to-treat cancers and will share new data from our broad thoracic development program at the upcoming WCLC."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.